These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 15312276)

  • 41. Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: a review.
    Leroi I; Collins D; Marsh L
    J Neurol Sci; 2006 Oct; 248(1-2):104-14. PubMed ID: 16806271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cannabidiol for the treatment of psychosis in Parkinson's disease.
    Zuardi AW; Crippa JA; Hallak JE; Pinto JP; Chagas MH; Rodrigues GG; Dursun SM; Tumas V
    J Psychopharmacol; 2009 Nov; 23(8):979-83. PubMed ID: 18801821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.
    Meco G; Bernardi S
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):311-3. PubMed ID: 16919377
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Neuropsychiatric and cognitive symptoms in Parkinson disease].
    Aarsland D; Pedersen KF; Ehrt U; Bronnick K; Gjerstad MD; Larsen JP
    Tidsskr Nor Laegeforen; 2008 Sep; 128(18):2072-6. PubMed ID: 18846124
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.
    Chang A; Fox SH
    Drugs; 2016 Jul; 76(11):1093-118. PubMed ID: 27312429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment options for non-motor symptoms in late-stage Parkinson's disease.
    Coelho M; Ferreira J; Rosa M; Sampaio C
    Expert Opin Pharmacother; 2008 Mar; 9(4):523-35. PubMed ID: 18312155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset.
    Giladi N; Weitzman N; Schreiber S; Shabtai H; Peretz C
    J Psychopharmacol; 2007 Jul; 21(5):501-6. PubMed ID: 17446202
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antipsychotic use in older adults with Parkinson's disease.
    Marras C; Kopp A; Qiu F; Lang AE; Sykora K; Shulman KI; Rochon PA
    Mov Disord; 2007 Feb; 22(3):319-23. PubMed ID: 17149718
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease.
    Feldman B; Chapman J; Korczyn AD
    Acta Neurol Scand; 2006 Jan; 113(1):14-7. PubMed ID: 16367893
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gastrointestinal symptoms in Parkinson's disease.
    Edwards LL; Pfeiffer RF; Quigley EM; Hofman R; Balluff M
    Mov Disord; 1991; 6(2):151-6. PubMed ID: 2057006
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of neurodegenerative disorders: Parkinson's disease and Alzheimer's disease.
    Pal PK; Netravathi M
    J Indian Med Assoc; 2005 Mar; 103(3):168-70, 172, 174-6. PubMed ID: 16173294
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Psychosis, apathy, depression and anxiety in Parkinson's disease.
    Gallagher DA; Schrag A
    Neurobiol Dis; 2012 Jun; 46(3):581-9. PubMed ID: 22245219
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Understanding Parkinson's disease: detection and early disease management.
    Mackin LA
    Lippincotts Prim Care Pract; 2000; 4(6):595-607. PubMed ID: 11933373
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Parkinson's psychosis.
    Zahodne LB; Fernandez HH
    Curr Treat Options Neurol; 2010 May; 12(3):200-11. PubMed ID: 20842582
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drugs to treat dementia and psychosis: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S120-7. PubMed ID: 12211152
    [No Abstract]   [Full Text] [Related]  

  • 57. [Treatment of mental disorders in patients with Parkinson's disease].
    Meincke U; Kosinski CM
    Fortschr Neurol Psychiatr; 2010 May; 78(5):279-87. PubMed ID: 20422492
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Parkinson's disease psychosis: presentation, diagnosis and management.
    Schneider RB; Iourinets J; Richard IH
    Neurodegener Dis Manag; 2017 Dec; 7(6):365-376. PubMed ID: 29160144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psychiatric aspects of Parkinson's disease--an update.
    Schrag A
    J Neurol; 2004 Jul; 251(7):795-804. PubMed ID: 15258780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.
    Hassin-Baer S; Cohen O; Vakil E; Sela BA; Nitsan Z; Schwartz R; Chapman J; Tanne D
    Clin Neuropharmacol; 2006; 29(6):305-11. PubMed ID: 17095893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.